Benign Prostatic Hyperplasia Pipeline 2024 | Gemvax & Kael, Antev, Dongkook Pharmaceutical, Chong Kun Dang Pharmaceutical, Resurge Therapeutics Inc., DMK Pharmaceuticals

(MENAFN- GetNews)

DelveInsight's,
“Benign Prostatic Hyperplasia Pipeline Insight 2024”
report provides comprehensive insights about
10+ companies and 10+ pipeline drugs
in Benign Prostatic Hyperplasia pipeline landscape. It covers the Benign Prostatic Hyperplasia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Benign Prostatic Hyperplasia Pipeline. Dive into DelveInsight's comprehensive report today! @ Benign Prostatic Hyperplasia Pipeline Outlook

Key Takeaways from the Benign Prostatic Hyperplasia Pipeline Report

• July 2024:- EMS- Phase III, Multicenter, Randomized, Double-blind Clinical Trial to Assess the Efficacy and Safety of the DTT106 in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia. The purpose of this study is to assess the safety and efficacy of the DTT106 in the treatment of erectile dysfunction associated with benign prostatic hyperplasia
• July 2024:- Vedic Lifesciences Pvt. Ltd.- The present study is a randomized, double-blind, placebo-controlled study. Approximately 125 individuals will be screened, and considering a screening failure rate of 20%, at least 100 will be randomized in a ratio of 1:1 to receive either IP or placebo and will be assigned a unique randomization code. Each group will have not less than 40 completed participants after accounting for a dropout/withdrawal rate of 20%. The intervention duration for all the study participants is 90 days.
• DelveInsight's Benign Prostatic Hyperplasia pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Benign Prostatic Hyperplasia treatment.
• The leading Benign Prostatic Hyperplasia Companies such as GemVax & Kael, Antev, Dongkook Pharmaceutical, Chong Kun Dang Pharmaceutical, Resurge Therapeutics Inc., DMK Pharmaceuticals, and others
• Promising Benign Prostatic Hyperplasia Therapies such as CKD-846, D091, Paclitaxel, alpha blocker and 5-alpha reductase inhibitor, DTT106, Dutasteride-Tamsulosin , and others.

Stay ahead with the most recent pipeline outlook for Benign Prostatic Hyperplasia. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Benign Prostatic Hyperplasia Treatment Drugs

Benign Prostatic Hyperplasia Emerging Drugs Profile

• DKF-313: Dongkook Pharmaceutical

DKF-313, a combination of dutasteride and tadalafil, is expected to reduce prostate size and improve dysuria symptoms caused by BPH more effectively than single drugs. This combination targets specific antigens overexpressed on cancer cells, allowing for selective targeting. By binding to these target antigens, DKF-313 can deliver the drugs directly to the affected cells, enhancing treatment outcomes. Currently, the drug is in Phase III stage of its clinical trial for the treatment of benign prostatic hyperplasia.

• Teverelix trifluoroacetate: Antev

Teverelix trifluoroacetate (Teverelix TFA) is a gonadotrophin-releasing hormone (GnRH) antagonist with a novel formulation. GnRH antagonists rapidly suppress the effects of sex hormones by limiting their production. This is therapeutically valuable for conditions that are controlled by sex hormone secretion, including prostate cancer, benign prostatic hyperplasia, and endometriosis. Recent data suggest that GnRH antagonists may have multiple therapeutic advantages over the traditionally used GnRH agonists, and therefore have the potential to supersede GnRH agonists as the gold-standard treatment. Currently, the drug is in Phase II stage of its clinical trial for the treatment of benign prostatic hyperplasia.

• DPI-221: DMK Pharmaceuticals

DPI-221 by DMK Pharmaceuticals is a drug that acts as a highly selective agonist for the δ-opioid receptor, known for producing fewer convulsions compared to other drugs in the same family. This drug is a novel nonpeptide delta receptor agonist that has shown effects such as increased micturition interval in normal rats. Currently, the drug is in Phase I stage of its clinical trial for the treatment of benign prostatic hyperplasia.

Explore groundbreaking therapies and clinical trials in the Benign Prostatic Hyperplasia Pipeline. Access DelveInsight's detailed report now! @ New Benign Prostatic Hyperplasia Drugs

Benign Prostatic Hyperplasia (BPH) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Benign Prostatic Hyperplasia Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Unveil the future of Benign Prostatic Hyperplasia Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Benign Prostatic Hyperplasia Market Drivers and Barriers

Scope of the Benign Prostatic Hyperplasia Pipeline Report

• Coverage- Global
• Benign Prostatic Hyperplasia Companies- GemVax & Kael, Antev, Dongkook Pharmaceutical, ChongKun Dang Pharmaceutical, Resurge Therapeutics Inc., DMK Pharmaceuticals, and others
• Benign Prostatic Hyperplasia Therapies- CKD-846, D091, Paclitaxel, alpha blocker and 5-alpha reductase inhibitor, DTT106, Dutasteride-Tamsulosin, and others.
• Benign Prostatic Hyperplasia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Benign Prostatic Hyperplasia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Benign Prostatic Hyperplasia Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Benign Prostatic Hyperplasia Companies, Key Products and Unmet Needs

Table of Content